1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006; 119:2922–2930.
Article
2. Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013; 108:727–734.
3. Foley OW, Rauh-Hain JA, Clemmer J, Clark RM, Hall T, Diver EJ, et al. Trends in the treatment of uterine leiomyosarcoma in the Medicare population. Int J Gynecol Cancer. 2015; 25:453–458.
Article
4. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116:131–139.
5. Kim WY, Chang SJ, Chang KH, Yoon JH, Kim JH, Kim BG, et al. Uterine leiomyosarcoma: 14-year two-center experience of 31 cases. Cancer Res Treat. 2009; 41:24–28.
6. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009; 104:177–178.
Article
7. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990; 162:968–974.
Article
8. Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol. 2003; 91:209–212.
Article
9. Schwartz Z, Dgani R, Lancet M, Kessler I. Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol. 1985; 20:354–363.
Article
10. Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2012; 118:660–669.
Article
11. Kempson RL, Bari W. Uterine sarcomas. Classification, diagnosis, and prognosis. Hum Pathol. 1970; 1:331–349.
12. Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. Hoboken (NJ): John Wiley & Sons;2013.
13. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on Surveillance, Epidemiology, and End Results Database. Int J Gynecol Cancer. 2016; 26:1098–1104.
Article
14. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008; 112:820–830.
15. Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, Trassard M, et al. Prognostic factors in early-stage leiomyosarcoma of the uterus. Int J Gynecol Cancer. 2009; 19:385–390.
Article
16. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009; 54:355–364.
Article
17. Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004; 92:648–652.
Article
18. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol. 1999; 74:196–201.
Article
19. Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study. Gynecol Oncol. 2017; 145:61–70.
Article
20. Leitao MM Jr, Zivanovic O, Chi DS, Hensley ML, O'Cearbhaill R, Soslow RA, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012; 125:409–413.
Article
21. Anderson TM, McMahon JJ, Nwogu CE, Pombo MW, Urschel JD, Driscoll DL, et al. Pulmonary resection in metastatic uterine and cervical malignancies. Gynecol Oncol. 2001; 83:472–476.
Article
22. Clavero JM, Deschamps C, Cassivi SD, Allen MS, Nichols FC 3rd, Barrette BA, et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg. 2006; 81:2004–2007.
Article
23. Leitao MM, Brennan MF, Hensley M, Sonoda Y, Hummer A, Bhaskaran D, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002; 87:287–294.
Article
24. Paik ES, Yoon A, Lee YY, Kim TJ, Lee JW, Bae DS, et al. Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors. J Gynecol Oncol. 2015; 26:270–276.
Article
25. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, et al. Uterine neoplasms. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009; 7:498–531.
26. Nishigaya Y, Kobayashi Y, Matsuzawa Y, Hasegawa K, Fukasawa I, Watanabe Y, et al. Diagnostic value of combination serum assay of lactate dehydrogenase, D-dimer, and C-reactive protein for uterine leiomyosarcoma. J Obstet Gynaecol Res. 2019; 45:189–194.
Article
27. Menczer J, Schreiber L, Berger E, Ben-Shem E, Golan A, Levy T. CA125 expression in the tissue of uterine leiomyosarcoma. Isr Med Assoc J. 2014; 16:697–699.